How Do Targeted Therapies Change the Management of Indolent Lymphomas?
- Published in:
- Oncology (08909091), 2016, v. 30, n. 9, p. 859
- By:
- Publication type:
- Article
Works matching IS 08909091 AND DT 2016 AND VI 30 AND IP 9
Results: 11
1
2
Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 9, p. 847
- By:
- Publication type:
- Article
3
When to Use Prophylactic Antibiotics in Neutropenic Patients.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 9, p. 838
- By:
- Publication type:
- Article
4
Rising PSA Level in an Anxious Postprostatectomy Patient.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 9, p. 834
- By:
- Publication type:
- Article
5
Data on Ductal Carcinoma In Situ Encumbered by Opinion.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 9, p. 832
- By:
- Publication type:
- Article
6
Current Trends in the Management of Ductal Carcinoma In Situ.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 9, p. 823
- By:
- Publication type:
- Article
7
ACR Appropriateness Criteria® Adjuvant Management of Early-Stage Endometrial Cancer.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 9, p. 816
- By:
- Publication type:
- Article
8
Third-Line Treatment Options for Kidney Cancer.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 9, p. 813
- By:
- Publication type:
- Article
9
Ready, Fire, Aim: Addressing Issues Associated With Multigene Panel Testing for Cancer Susceptibility.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 9, p. 800
- By:
- Publication type:
- Article
10
What's New in Genetic Testing for Cancer Susceptibility?
- Published in:
- Oncology (08909091), 2016, v. 30, n. 9, p. 787
- By:
- Publication type:
- Article
11
Q&A.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 9, p. 770
- By:
- Publication type:
- Article